RUB » Bibliotheksportal

Anna Lena Fisse, Emelie Schäfer, Alina Hieke, Maximilian Schröder, Rafael Mattias Klimas, Jil Brünger, Sophie Huckemann, Thomas Grüter, Melissa Sgodzai, Christiane Schneider-Gold, Ralf Gold, Huu Phuc Nguyen, Kalliopi Pitarokoili, Jeremias Motte, Larissa Arning

• \(\textbf {Background and purpose:}\) Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease with humoral and cellular autoimmunity causing demyelination of peripheral nerves, commonly treated with intravenous immunoglobulins (IVIg). The neonatal Fc receptor (FcRn), encoded by the \(\it FCGRT\) gene, prevents the degradation of immunoglobulin G (IgG) by recycling circulating IgG. A variable number of tandem repeat (VNTR) polymorphism in the promoter region of the \(\it FCGRT\) gene is associated with different expression levels of mRNA and protein. Thus, patients with genotypes associated with relatively low FcRn expression may show a poorer treatment response to IVIg due to increased IVIg degradation. \(\bf Methods:\) VNTR genotypes were analyzed in 144 patients with CIDP. Patients' clinical data, including neurological scores and treatment data, were collected as part of the Immune-Mediated Neuropathies Biobank registry. \(\bf Results:\) Most patients (\(\it n\) = 124, 86%) were VNTR 3/3 homozygotes, and 20 patients (14%) were VNTR 2/3 heterozygotes. Both VNTR 3/3 and VNTR 2/3 genotype groups showed no difference in clinical disability and immunoglobulin dosage. However, patients with a VNTR 2 allele were more likely to receive subcutaneous immunoglobulins (SCIg) than patients homozygous for the VNTR 3 allele (25% vs. 9.7%, \(\it p\) = 0.02) and were more likely to receive second-line therapy (75% vs. 54%, \(\it p\) = 0.05). \(\bf Conclusions:\) The VNTR 2/3 genotype is associated with the administration of SCIg, possibly reflecting a greater benefit from SCIg due to more constant immunoglobulin levels without lower IVIg levels between the treatment circles. Also, the greater need for second-line treatment in VNTR 2/3 patients could be an indirect sign of a lower response to immunoglobulins.